Abstract
The COVID-19 pandemic of 2020 prompted stringent mitigation measures to “flatten the curve” quickly leading to an asphyxiated US economy as a national side effect. There are severe drawbacks to this strategy. The resulting flattened curve remains exponential and always under utilizes available healthcare capacity with a chance of still overburdening it. Moreover, while a mitigation strategy involving isolation and containment can scale down infections, it not only prolongs the outbreak significantly, but also leaves a susceptible population in its wake that’s ripe for a secondary outbreak. Since economic activity is inversely proportional to mitigation, curtailing the outbreak with sustained mitigation can stifle the economy severely with disastrous repercussions. Full mitigation for the duration of an outbreak is therefore unsustainable and, overall, a poor solution with potentially catastrophic consequences that could’ve been avoided. A new strategy, coined a “Method for Active Pandemic Curve Management”, or MAPCM, presented herein can shape the outbreak curve in a controlled manner for optimal utilization of healthcare resources during the pandemic, while drastically shortening the outbreak duration compared to mitigation by itself without trading off lives. This method allows mitigation measures to be relaxed gradually from day one, which enables economic activity to resume gradually from the onset of a pandemic. Since outbreak curves (such as hospitalizations) can be programmed using this method, they can also be shaped to accommodate changing needs during the outbreak; and to build herd immunity without the damaging side effects. The method can also be used to ease out of containment. MAPCM is a method and not a model. It is compatible with any appropriate outbreak model; and herein it is illustrated in examples using a hybrid logistic model.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
There were no trials in the study.
Funding Statement
This work was not funded
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is publicly available and has been widely distributed.
